Xenon Pharmaceuticals Inc.

Inspire Pharmaceuticals, Inc.

Chi Tu

Melwyn A Abreo

Shaoyi Sun

Serguei Sviridov

Rajender Kamboj

Shifeng Liu

Vishnumurthy Kodumuru

Michael D Winther

Heinz W Gschwend

Daniel F Harvey

Wenbao Li

Zaihui Zhang

Mark W Holladay

Vandna Raina

Sammy Ray Shaver

José L Boyer

Robert Plourde, Jr

Yangbo Feng

Lorenzo Josue Alfaro-Lopez

Tatyana V Khasonova

Sultan Chowdhury

Mikhail A Chafeev

Jian-Min Fu

Paul Steven Watson

Nagasree Chakka

James G Douglass, Iii

Duanjie Hou

Mehran Seid Bagherzadeh

Mikhail Kondratenko

Sengen Sun

Cindy J Hudson

Robert Fraser

Kashinath Sadalapure

Tatyana V Khasanova

Mikhail A Kondratenko

Jian-min Fu

Mikhail Chafev

Kashinath Sadalupure

Sun Shaoyi

Michael Winther

Heinz Gschwend

Melwyn Anthony Abreo

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): 

Pyridyl derivatives and their use as therapeutic agents

Piperazine derivatives as stearoyl-coa desaturase inhibitors and their use as therapeutic agents

This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Yreceptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.

Non-nucleotide composition for inhibiting platelet aggregation

This invention is directed to the use of SCD-1 inhibitors of the formula (I): where x, y, V, W, G, J, L, M, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein, in combination with other drug therapies to treat adverse weight gain. 

Combination therapy

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (Ia): where x, y, W, V, R, R, R, R, R, R, R, R, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Pyridazine derivatives and their use as therapeutic agents

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): wherein: W is &#x2014;O&#x2014;, &#x2014;N(R1)&#x2014;, C(O), S(O)t; (where t is 0, 1 or 2), N(R1)S(O)2, S(O)2N(R1), C(O)N(R1) or N(R1)C(O)N(R1); and V is C(O), C(S), C(O)N(R1)&#x2014;, C(O)O&#x2014;, S(O)2&#x2014;, S(O)2N(R1)&#x2014; or C(R11)H; and x, y, R1, R2, R3, R4, R5, R6, R7, R7, R8, R8, R9, R9, R10 and R10are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. 

This invention is directed to compounds of Formulae III and V, useful for treating diseases or conditions associated with platelet aggregation. 

Non-nucleotide composition and method for inhibiting platelet aggregation

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where G, J, L, M, x, y, W, V, R, R, R, R, R, R, R, R, R, R, R, R, Rand Ra are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. 

Piperazine derivatives and their use as therapeutic agents

This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound, preferably a P2Yreceptor antagonist compound, wherein said amount is effective to inhibit platelet aggregation. The compounds useful for this invention include compounds of general Formula I and III-XI, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds according to Formula I and III-XI.

Non-nucleotide compositions and method for inhibiting platelet aggregation

This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a compounds useful for this invention include compounds of general Formulae I and III-XII, or salts, hydrates, and solvates thereof. The present invention also provides novel compounds of Formulae I and III-XII.

Growing community of inventors

San Diego, CA, United States of America

Chi Tu